


Product Information



NO-Pravastatin

Catalog No. 10006044

CAS Registry No.: 733034-46-3
Formal Name: 1S,2S,6S,7,8S,8aR-hexahydro- β , δ ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-4-(nitrooxy)butyl ester, 1-naphthaleneheptanoic acid
Synonym: NCX 6550
MF: C₂₈H₄₅NO₉
FW: 539.7
Purity: \geq 95%
Stability: \geq 2 years at -20°C
Supplied as: A crystalline solid



Laboratory Procedures

For long term storage, we suggest that NO-pravastatin be stored as supplied at -20°C. It should be stable for at least two years.

NO-pravastatin is supplied as a crystalline solid. A stock solution may be made by dissolving the NO-pravastatin in an organic solvent purged with an inert gas. NO-pravastatin is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of NO-pravastatin in these solvents is approximately 30 mg/ml.

NO-pravastatin is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, NO-pravastatin should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. NO-pravastatin has a solubility of approximately 0.5 mg/ml in a 1:1 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

The 'statin' class of drugs, which includes lovastatin, simvastatin, fluvastatin, atorvastatin, cerivastatin, and pravastatin, inhibits the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and are widely used for the treatment of hypercholesterolemia.¹ NO-pravastatin is a hybrid molecule containing a nitric oxide (NO) releasing moiety combined with the HMG-CoA reductase inhibitor pravastatin.² These combined functionalities produce a compound with a unique spectrum of pharmacological activities. NO-pravastatin inhibits the proliferation of rat aortic smooth muscle cells with an IC₅₀ value of 2.2 μ M, whereas pravastatin showed minor inhibition even at 100 μ M.² A potential anti-inflammatory effect of NO-pravastatin may result from its direct inhibition of iNOS and cyclooxygenase-2 gene expression in lipopolysaccharide-activated RAW 264.7 cells.

References

1. Maron, D.J., Fazio, S., and Linton, M.F. Current perspectives on statins. *Circulation* **101**, 207-213 (2000).
2. Ongini, E., Impagnatiello, F., Bonazzi, A., *et al.* Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhanced antiproliferative and antiinflammatory properties. *Proc. Natl. Acad. Sci. USA* **101**(22), 8497-8502 (2004).

Related Products

NO-Indomethacin - Cat. No. 10005705 • NO-Ibuprofen - Cat. No. 10005706 • NO-Aspirin 1 - Cat. No. 10005854 • NO-Aspirin 2 - Cat. No. 10005856 • NO-Flurbiprofen - Cat. No. 10005857 • NO-Fluvastatin - Cat. No. 10006043

Cayman Chemical

Mailing address
1180 E. Ellsworth Road
Ann Arbor, MI
48108 USA

Phone
(800) 364-9897
(734) 971-3335

Fax
(734) 971-3640

E-Mail
custserv@caymanchem.com

Web
www.caymanchem.com

WARNING: THIS PRODUCT IS FOR LABORATORY RESEARCH ONLY: NOT FOR ADMINISTRATION TO HUMANS. NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

MATERIAL SAFETY DATA

This material should be considered hazardous until information to the contrary becomes available. Do not ingest, swallow, or inhale. Do not get in eyes, on skin, or on clothing. Wash thoroughly after handling. This information contains some, but not all, of the information required for the safe and proper use of this material. Before use, the user must review the complete Material Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Cayman Chemical Company makes **no warranty or guarantee** of any kind, whether written or oral, expressed or implied, including without limitation, any warranty of fitness for a particular purpose, suitability and merchantability, which extends beyond the description of the chemicals hereof. Cayman **warrants only** to the original customer that the material will **meet our specifications at the time of delivery**.

Cayman will carry out its delivery obligations with due care and skill. Thus, in no event will Cayman have **any obligation or liability**, whether in tort (including negligence) or in contract, for any direct, indirect, incidental or consequential damages, even if Cayman is informed about their possible existence.

This limitation of liability does not apply in the case of intentional acts or negligence of Cayman, its directors or its employees.

Buyer's **exclusive remedy** and Cayman's sole liability hereunder shall be limited to a **refund** of the purchase price, or at Cayman's option, the **replacement**, at no cost to Buyer, of all material that does not meet our specifications.

Said refund or replacement is conditioned on Buyer giving written notice to Cayman within thirty (30) days after arrival of the material at its destination. Failure of Buyer to give said notice within thirty (30) days shall constitute a waiver by Buyer of all claims hereunder with respect to said material.

For further details, please refer to our **Warranty and Limitation of Remedy located on our website and in our catalog**.

Copyright Cayman Chemical Company, 02/12/2010